Skip to content
Screener

Exelixis EXEL CABOMETYX — Total revenues

Other product segments

Gross product revenues
$812.78M+9.1%
Discounts and allowances
-$239.76M-6.4%
License revenues
$59.81M+21.3%
Collaboration
$55.67M+15.4%
Collaboration services revenues
-$4.53M-80.8%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
CABOMETYX$570,648$517,890$1,123,421$1,028,762
COMETRIQ2,3772,1244,5814,535
Net product revenues$573,025$520,014$1,128,002$1,033,297

Item 1. Financial Statements.

FAQ

What is Exelixis's CABOMETYX — total revenues?
Exelixis (EXEL) reported CABOMETYX — total revenues of $570.65M in Q2 2026.
How has Exelixis's CABOMETYX — total revenues changed year-over-year?
Exelixis's CABOMETYX — total revenues increased by 10.2% year-over-year, from $517.89M to $570.65M.
What is the long-term trend for Exelixis's CABOMETYX — total revenues?
Over 4 years (2021 to 2025), Exelixis's CABOMETYX — total revenues has grown at a 19.0% compound annual growth rate (CAGR), from $1.05B to $2.11B.
What does CABOMETYX — total revenues mean?
This metric represents the total gross revenue generated from the sale of the company's primary oncology therapeutic product, Cabometyx. It reflects the commercial success and market adoption of this specific drug across its approved indications, including renal cell carcinoma and hepatocellular carcinoma. This figure is a critical indicator of the company's core product performance and its ability to maintain market share in the competitive oncology landscape.

Ask your AI about Exelixis's cabometyx — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude